Assembly Biosciences Inc (ASMB) Expected to Announce Earnings of -$1.02 Per Share

Share on StockTwits

Analysts expect Assembly Biosciences Inc (NASDAQ:ASMB) to post ($1.02) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Assembly Biosciences’ earnings, with estimates ranging from ($1.15) to ($0.94). Assembly Biosciences reported earnings per share of ($0.71) during the same quarter last year, which would indicate a negative year-over-year growth rate of 43.7%. The company is scheduled to announce its next quarterly earnings results on Wednesday, November 7th.

On average, analysts expect that Assembly Biosciences will report full year earnings of ($4.12) per share for the current fiscal year, with EPS estimates ranging from ($4.51) to ($3.76). For the next fiscal year, analysts anticipate that the firm will report earnings of ($3.99) per share, with EPS estimates ranging from ($5.35) to ($2.27). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($1.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($0.42). The company had revenue of $3.22 million during the quarter, compared to the consensus estimate of $3.30 million. Assembly Biosciences had a negative net margin of 457.20% and a negative return on equity of 66.34%.

Several research analysts have issued reports on ASMB shares. ValuEngine raised Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. B. Riley dropped their price target on Assembly Biosciences to $45.00 and set a “neutral” rating on the stock in a report on Tuesday, May 8th. Zacks Investment Research raised Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, July 10th. Robert W. Baird started coverage on shares of Assembly Biosciences in a research report on Wednesday, August 8th. They set an “outperform” rating and a $74.00 price objective on the stock. Finally, BidaskClub cut shares of Assembly Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, July 13th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. Assembly Biosciences currently has a consensus rating of “Hold” and an average target price of $63.20.

In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $38.50, for a total transaction of $38,500.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Derek A. Small acquired 2,400 shares of the stock in a transaction on Thursday, July 19th. The shares were purchased at an average price of $41.48 per share, for a total transaction of $99,552.00. Following the completion of the transaction, the chief executive officer now owns 668,091 shares in the company, valued at approximately $27,712,414.68. The disclosure for this purchase can be found here. Insiders own 18.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of ASMB. Bank of Montreal Can purchased a new position in Assembly Biosciences during the 2nd quarter worth approximately $145,000. Quantbot Technologies LP purchased a new position in Assembly Biosciences during the 1st quarter worth approximately $154,000. Jane Street Group LLC purchased a new position in shares of Assembly Biosciences during the 1st quarter valued at $204,000. MetLife Investment Advisors LLC purchased a new position in shares of Assembly Biosciences during the 2nd quarter valued at $282,000. Finally, Quantitative Systematic Strategies LLC purchased a new position in shares of Assembly Biosciences during the 2nd quarter valued at $348,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

NASDAQ ASMB opened at $36.03 on Friday. The firm has a market capitalization of $930.07 million, a price-to-earnings ratio of -14.95 and a beta of 0.86. Assembly Biosciences has a 1 year low of $24.74 and a 1 year high of $67.36.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Featured Article: Average Daily Trade Volume – What It Means In Stock Trading

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply